Cognition Life Science hires Chuanhai Cao as Chief Scientific Officer

Cao is a top researcher at the University of Southern Florida in Tampa

Cognition Life Science (CLS), a new pharmaceutical company located in Tampa, Florida, has hired Dr Chuanhai Cao as Chief Scientific Officer and has acquired his intellectual property, which includes novel formulations to treat Alzheimer's Disease, Parkinson's Disease, sleep disorders and mental acuity.

Cao was one of the first scientists to determine that THC can halt and reverse the symptoms of Alzheimer's Disease. He developed a therapeutic vaccine for the treatment of Alzheimer's Disease and for certain forms of cancer.

CLS has issued Cao 13.5 million common shares and will pay him US$5m upon certain milestone achievements. Cao will be spending a some of his time attending to his duties at CLS and will be responsible for a budget in excess of $1m.

Cao is a research scientist at the College of Medicine Neurology and Assistant Professor of Cop. Department of Pharmaceutical Science at USF/Byrd Institute in Tampa, Florida.

You may also like

Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Manufacturing

Five critical design elements for Pelton wheel turbine flowmeters

Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Subscribe now